Advanced Search

The American Journal of Psychiatry, VOL. 159, No. 2

Letter to the Editor | February 01, 2002

Dr. Sernyak and Colleagues Reply

MICHAEL J. SERNYAK, M.D.; RANI DESAI, PH.D.; ROBERT ROSENHECK, M.D.

Am J Psychiatry 2002;159:324-324. 10.1176/appi.ajp.159.2.324

text A A A

To the Editor: We welcome the chance to respond to the questions raised by Drs. Ertugrul and Meltzer because it provides us with an additional opportunity to explain why we feel our assessment that clozapine is not associated with a lower than usual risk of suicide is based on a more sound evaluation method than in previous studies.

Dr. Ertugrul’s letter confirms our primary claim that previous studies of this issue have employed mostly weak designs. The most informative control groups had characteristics demonstrably similar to those of the specified treatment groups in every respect except treatment assignment. As summarized by Dr. Ertugrul, previous studies have employed historical control groups (Meltzer and Okayli, 1995), control groups about which so little is known that comparability could not be assessed (Reid et al., 1998), and control groups that have included no patients who were not previously exposed to clozapine (Walker et al., 1997). Thus, we feel that Dr. Ertugrul’s comments provide substantial support for our evaluation of the literature.

Dr. Meltzer asserts that we did not match for the "four most important" variables for the matching for suicide risk in patients with schizophrenia. While we agree that this is a limitation, as discussed at length in our article, it applies to all of the studies on this subject. Dr. Meltzer draws special attention to the fact that when the patients never exposed to clozapine were compared with the patients who had been receiving clozapine for more than 12 months (groups that exclude many who showed no improvement while taking clozapine), there was a trend (at the p=0.10 level) for those receiving clozapine to have a lower rate of suicide. We do not think this was a relevant comparison for evaluating the effect of clozapine on suicidal risk.

The comparison that best reflects clinical practice and is most informative compares all patients who received clozapine with a carefully matched group of patients who were never exposed to clozapine, yielding a nonsignificant (p=0.76) difference in the rates of suicide. We presented the comparison between those who completed 1 year of treatment (excluding a large number of treatment nonresponders) and the entire control group (from which nonresponders had not been excluded) to illustrate the bias inherent in previous studies comparing patients who dropped out of treatment and those who continued. The fact that this highly biased comparison still failed to yield a significantly lower rate of suicide in our study adds further support to the nonsignificant findings of our main analysis.

We appreciate the thoughtful comments of our colleagues, which allowed us to emphasize and further clarify some of the more informative points of our analysis.

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.

Submit a Comments

Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

* = Required Field

Comment Author(s)*(if multiple authors, separate names by comma)

Example: John Doe

Affiliation & Institution*

Comment Title*

Comment*

Cancel

Print
E-mail

Recipient(s) will receive an email with a link (good for 72 hours) to 'Dr. Sernyak and Colleagues Reply' and do not need to have American Journal of Psychiatry account to access the content.
Your Name:*
Example: John Doe

Email Address:* CC Me:
Enter your valid email address. Example: jdoe@example.com

Recipient's Email Address:*
Separate multiple email address with semi-colons (up to 5).

Subject:* 's American Journal of Psychiatry: 'Dr. Sernyak and Colleagues Reply'
Subject for your email.

Message:
(Optional, message will truncate at 1000 characters)

Processing your request... Please Wait...

Copyright © in the material you requested is held by The American Psychiatric Association (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to The American Psychiatric Association's Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to The American Psychiatric Association's Privacy Policy for further information.

Copyright © American Psychiatric Association. All rights reserved.
Share
Get Citation

MICHAEL J. SERNYAK, RANI DESAI, ROBERT ROSENHECK; Dr. Sernyak and Colleagues Reply. American Journal of Psychiatry. 2002 Feb;159(2):324-324.

Download citation file:

RIS (Zotero)

EndNote

BibTex

Medlars

ProCite

RefWorks

Reference Manager

Copyright © American Psychiatric Association. All rights reserved.
Reprints